Videos

BioPharm International® spoke with Lun Xin, associate director at WuXi Biologics, about high-concentration biologics and some of the biggest challenges associated with their formulation.

AAPS National Biotechnology Conference 2025: High-Concentration Biologics

Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

The PharmTech Group interviewed Edwin Stone, CEO of Cellular Origins, about how technological advances will impact the biopharma industry in the future.


Industry Outlook 2025: The Future of Technology in the Biopharma Industry

BioPharm International® sat down with Noah Kopcho, field application scientist at Gyros Protein Technologies, to talk about the challenges in the production of AAV vectors.

AAPS National Biotechnology Conference 2025: AAV Vector Production

Patrick Lavery is an Editor for the MJH Life Sciences brands 

. Previously at MJH, he filled the same role for 

Articles

The company is presenting data related to its medications designed to advance the prevention and treatment of asthma and COPD.

GSK Previews Oral and Poster Abstracts for ATS International Congress

The pandemic made it daunting for companies to retain talent and then find it anew, but just as that cloud is lifting and workforce diversity is being embraced, AI beckons as a new challenge.

Authentic Intelligence: Finding Diverse Talent in the Age of AI

Cheryl Barton is director of PharmaVision, 

The European Union is discussing ways to reduce Europe’s over-reliance on imports of APIs.

EU to Support the Production of APIs and Finished Medicines within Europe  

Siegfried Schmitt, PhD, is Vice President Technical at Parexel International, Siegfried.Schmitt@parexel.com.

While global harmonization exists, there are still differences between the US and European GMP requirements that manufacturers should know, says Siegfried Schmitt, PhD, vice president, Technical at Parexel.

Complying with European versus US GMPs 

Aviva Capital Partners and developer Socius are investing £1 billion to develop a cancer research and treatment center in Sutton, London.

Cancer Research and Treatment Center Planned for London

Mike Hennessy Jr. is the Chairman and CEO of 

The pharma industry is focused on strengthening its foundation, embracing innovation, and future-proofing its path forward.

Quality, Resilience, and Reinvention in Pharma Manufacturing

Bempikibart (ADX-914) is a human anti-IL-7Rα antibody that blocks the IL-7 and TSLP pathways, which have been implicated in driving T cell-mediated pathological processes in autoimmune diseases.

News